JP Morgan Chase
LKFT

JP Morgan Chase’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

JP Morgan Chase’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$840K – 7530
2025
Q2 		$840K Hold
30,000
– – ﹤0.01% 4491
2025
Q1 		$754K Buy
+30,000
New +$758K ﹤0.01% 4530
2023
Q1 		– Sell
-23,800
Closed -$1.06M – 6905
2022
Q4 		$1.06M Buy
+23,800
New +$1M ﹤0.01% 4000
2022
Q3 		– Sell
-11,900
Closed -$664K – 6598
2022
Q2 		$664K Buy
+11,900
New +$706K ﹤0.01% 4376

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's LKFT Position: Q1 2026 in Review

JP Morgan Chase reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 37% in Q1 2026, selling an estimated $2.95K and leaving 150 shares worth $4.33K. The position accounts for ﹤0.01% of the portfolio, ranked #6907.

JP Morgan Chase first reported a position in LKFT in Q3 2017 and has held it in 31 quarters since. The position peaked at $18.6M in Q1 2022. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • JP Morgan Chase held 150 shares of Lakefront Biotherapeutics American Depositary Shares worth $4.33K as of Q1 2026.
  • JP Morgan Chase sold 89 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $2.95K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6907 holding.
  • JP Morgan Chase first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2017 and has held it in 31 quarters since.
  • JP Morgan Chase's Lakefront Biotherapeutics American Depositary Shares position peaked at $18.6M in Q1 2022.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.